USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
DOR BIOPHARMA, INC.
Address:
29 Emmons Dr
PRINCETON, NJ
Phone:
N/A
URL:
N/A
EIN:
141150502
DUNS:
153880778
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,409,870.00 3

Award List:

Enteric-Coated Oral Beclomethasone Dipropionate in Patients with Acute Enteritis

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$509,870.00
Agency:
HHS
Principal Investigator:
Christopher J. Schaber
Abstract:
DESCRIPTION (provided by applicant): Acute radiation enteritis is caused by radiation-induced death of the normal cells in the lining of the bowel. As bowel cells die and are not replaced, gastrointestinal toxicity develops over the next few days and w eeks with chronic diarrhea, vomiting and… More

Beclomethasone post exposure therapy for gastrointestinal acute radiation syndrom

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Kevin J. Horgan – 310-206-3580
Abstract:
DESCRIPTION (provided by applicant): This proposal concerns the use of beclomethasone dipropionate (BDP) as a post-exposure drug therapy having the potential to mitigate the gastrointestinal (GI) injury associated with acute radiation syndrome (ARS) following exposure to intense ionizing radiation.… More

IND 20212 (03-25-99) PHASE 2: ORBEC (ORAL BDP)-PATIENTS WITH CHRONIC GVHD

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$300,000.00
Agency:
HHS
Principal Investigator:
Kevin J. Horgan – 310-206-3580
Abstract:
DESCRIPTION (provided by applicant): Graft vs. Host Disease (GVHD) is an expensive life-threatening complication following allogeneic hematopoietic cell transplantation in some patients that receive this life-saving treatment for certain cancers. The proposed open-label, multi-center, two-part… More